Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT 2: tepotinib with or without osimertinib after osimertinib resistance in MET-amplified EGFR-mutant NSCLC
NL-OMON52430Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tepotinib and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Objective response rate by independent review committee. Started Jan 2020; status: active, not recruiting.
02
Drugs
tepotinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52430.